MSMarie Sébert

Marie Sébert

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Marie Sébert has a total of 326 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Mesenchymal stromal cells drive immune escape in MDS and sAML through metabolic rewiring of NK cells

    by Valeria Bisio, Bérénice Schell, Maria Kalogeraki, Ines M’SIbih, Lin Pierre Zhao, Andrea Federici, Shaina Mougammadou, Emilie Lereclus, Loera Aguinaga, Pierre Walczak, et al.

    Myelodysplastic neoplasms (MDS) are clonal hematopoietic stem cell disorders that frequently progress to secondary acute myeloid leukemia (sAML). Besides intrinsic genetic changes, the disease’s development is heavily influenced by the bone marrow (BM) microenvironment, especially mesenchymal stromal cells (MSCs). In this study, we present a comprehensive characterization of how unhealthy MSCs affect natural killer (NK) cell anti-leukemic function in MDS and sAML. Using integrated ATAC-seq and RNA-seq profiling, we show that MDS/sAML-derived MSCs induce profound chromatin remodeling in NK cells, marked by reduced promoter accessibility and downregulation of genes essential for stress response and survival. Functionally, pathological MSCs fail to deliver the protective support normally provided by healthy MSCs, instead driving mitochondrial fragmentation and apoptosis in NK cells, ultimately suppressing their cytotoxic activity. Together, these findings reveal a previously unrecognized loss of supportive capacity in pathological MSCs that hampers NK-cell fitness. Therapeutic approaches that bolster mitochondrial resilience in NK cells may help counteract this microenvironment-induced impairment and strengthen immune surveillance in MDS and sAML.

  • Ivosidenib monotherapy in IDH1 mutated myelodysplastic neoplasm/syndrome

    by Marie Sébert, Emmanuelle Clappier, Sylvie Chevret, Hugo Bergugnat, Odile Rauzy, Aspasia Stamatoullas, Sophie Dimicoli-Salazar, Lamya Ait Si Selmi, Cendrine Chaffaut, Fatiha Chermat, et al.

  • Splicing-associated network PAK1-CLK1/4-SRRM1 is a vulnerability to overcome chemoresistance in human and mouse acute myeloid leukemia

    by Camille Vaganay, Frank Ling, Lois M. Kelly, Juliette Charles, Paul-Arthur Meslin, Hélène Pasquer, Rathana Kim, Marie Passet, Matthieu Duchmann, Léa Pelissier-Menjaud, et al.

    Chemotherapy resistance in acute myeloid leukemia (AML) remains a major clinical challenge. Integration of multiomic profiling and in vivo functional genomics revealed splicing dysregulation as a determinant of chemoresistance in AML. We uncovered a network involving the splicing regulator SRRM1 and the CLK1/4 and PAK1 kinase families as vulnerabilities in chemoresistant AML cells. Both kinase families are hyperactivated in chemoresistant cells, promoting SRRM1 phosphorylation and altering its scaffolding function. We also identified a relapse-associated PAK1 variant, c.1429G>T p.(Ala 477 →Ser), that confers chemotherapy resistance. Combined PAK1 and CLK1/4 inhibition recapitulated the splicing changes induced by SRRM1 loss, preferentially targeting chemoresistant AML and enhancing chemotherapy efficacy in cell lines, primary cells, and mouse models. Last, we pinpointed MAP2K5 as a critical downstream effector because missplicing of exons 17 and 18 of MAP2K5 upon SRRM1 depletion sensitized cells to chemotherapy. Our findings highlight a therapeutic strategy to overcome AML relapse by targeting splicing dysregulation.

  • Predisposition to ALL and Solid Tumors Rather Than Bone Marrow Failure in FANCM -Associated Fanconi Anemia

    by Francesco Pegoraro, Lise Larcher, Rathana Kim, Mélanie Pagès, Marie Passet, Aurélie Caye-Eude, Mony Fahd, Benoit Brethon, Lucie Hernandez, Nadia Vasquez, et al.

    PURPOSE: Fanconi anemia (FA) is a genetic disorder typically characterized by progressive bone marrow failure (BMF) during childhood, leading to diagnosis at that stage. In adolescence or adulthood, patients are predisposed to myelodysplastic syndrome (MDS), acute myeloid leukemia, and solid tumors. However, some individuals present atypically, delaying FA recognition and resulting in life-threatening complications. This study describes the distinctive phenotype associated with biallelic FANCM pathogenic variants. PATIENTS AND METHODS: Clinical and biologic data were analyzed from eight patients carrying biallelic germline FANCM pathogenic variants within a French cohort of 411 patients with FA (2.0%). Clinical outcomes were compared with those of patients with FA carrying non- FANCM variants. RESULTS: None of the eight FANCM patients developed BMF, contrasting with a 93.5% cumulative incidence among other FA genotypes ( P < .0001). This absence of marrow failure resulted in delayed FA diagnosis (median age 23.5 v 6.8 years, P < .01). Instead, six patients initially presented with malignancy and exhibited marked toxicity to conventional cancer therapies, prompting FA testing. Malignancies included four oral cancers and, unexpectedly, two ALL: a ZNF384-rearranged B-cell precursor ALL and a BCL11B::HOXA13 early T-cell precursor ALL. No ALL cases occurred among the 403 non- FANCM patients with FA ( P < .0001). The treatment courses of the two FANCM -related ALL cases are reported. CONCLUSION: Biallelic FANCM variants define a distinct FA subtype lacking early BMF, leading to missed diagnoses and severe toxicity upon malignancy. Recognizing this presentation is crucial for timely FA detection and for implementing adapted therapeutic and follow-up strategies.


  • Characteristics and prognostic significance of myelodysplasia-related features in VEXAS syndrome

    by Lin-Pierre Zhao, Olivier Kosmider, Maël Heiblig, Thomas Moulinet, Valentin Lacombe, Thibault Comont, Hervé Lobbes, Jean-Denis Karam, Louis Terriou, Samuel Ardois, et al.


  • Open Access

    Allogeneic hematopoietic stem cell transplantation in patients with germ line DDX41 mutated myeloid malignancies

    by Michael Loschi, Marie-Charlotte Villy, Jacques-Emmanuel Galimard, Marie-Mathilde Auboiroux, Nathalie Gachard, Alexandre Perani, Matthieu Duchmann, Laetitia Largeaud, Stéphanie Nguyen, Flore Sicre de Fontbrune, et al.

    Germ line DDX41 mutations (DDX41mut) are identified in ∼5% of myeloid malignancies with an excess of blasts, representing a distinct myelodysplastic syndrome (MDS)/acute myeloid leukemia (AML) entity. The disease is associated with better outcomes than DDX41 wild-type (DDX41WT) cases, but patients who do not undergo allogeneic hematopoietic stem cell transplantation (HSCT) may experience late relapse. Because of the recent identification of DDX41mut, data on the post-HSCT outcomes remain limited. In this study, we report the HSCT outcomes of 83 patients with DDX41mut MDS/AML. With a median follow-up of 4.4 years, the 2-year leukemia-free survival (LFS) was 68.6% (95% confidence interval [CI], 57.1-77.6) and the 2-year nonrelapse mortality (NRM) was 21.1% (95% CI, 12.9-30.6). We then assessed the impact of DDX41mut using a pair match analysis performed on patients who underwent a transplantation in AML clinical trials. No significant differences were observed between patients with DDX41mut and those with DDX41WT in terms of LFS at 2 years (hazard ratio, 1.06; 95% CI, 0.59-1.90; P = .84), overall survival, NRM, relapse, or graft-versus-host disease incidence. The cumulative incidence of relapse for DDX41mut showed a trend toward a lower relapse rate during the first year then higher after 1 year. Given the familial nature of the disease, we specifically examined patients who relapsed after HSCT with a related donor and identified 7 cases of DDX41mut donor cell leukemia. In this study, HSCT in patients with DDX41mut AML was not associated with an increased risk for toxicity. However, we observed a potential for later relapse, which could potentially be mitigated by selecting related donors based on DDX41 status.


  • Myeloid neoplasms risks for germline DDX41 pathogenic variants carriers

    by Marie-Charlotte Villy, Youenn Drouet, Lise Larcher, Yoann Vial, Benjamin Dauriat, Léa Veyrune, Laurène Fenwarth, Marie-Mathilde Auboiroux, Lucie Freiman, Sophie Nambot, et al.

    Monoallelic germline DDX41 pathogenic variants (PV) are responsible for the most frequent monogenic predisposition to myeloid neoplasms (MN), i.e., to myelodysplastic syndrome and acute myeloid leukemia. MN are rare clonal diseases affecting hematopoietic tissues, and curative approaches frequently implicate hematopoietic stem cell transplantation, requesting testing for relatives of DDX41-mutated MN patients. Establishing the penetrance of germline DDX41 PV is crucial to determine how to monitor the unaffected relatives who carry the familial DDX41 PV. Our study aims to assess the risk of MN in relatives of affected DDX41 carriers using the Genotype-Restricted-Likelihood (GRL) approach. We identified 63 families with probands carrying a germline DDX41 PV (ACMG class 4 or class 5 variant) affected with MN, from 11 French centers. One hundred and sixty relatives, including 73 males (46%), were genotyped at the median age of 51 [range: 15–84] years, 80 of them (50%) being carriers of the familial DDX41 PV. The cumulative risk of MN at 70 years for DDX41 PV carriers was estimated at 19.5% [95% CI: 5.8%–62.5%], corresponding to a relative risk compared to the general population of 55 [95% CI: 16.4–176.5]. This risk appeared higher in males, although the difference did not reach statistical significance. Based on these findings, we suggest yearly complete blood count from the age of 50 for DDX41 PV carriers. Of note, we observed cases before the age of 50 in females, which could suggest sex-differentiated monitoring.


  • IPSS-M risk and specific sex-associated somatic mutations predict response to ESA therapy in LR-MDS: building a new score

    by Marco G. Raddi, Sophie Park, Michaela Fontenay, Olivier Kosmider, Maria Diez Campelo, Juan C. Berrocal, Marie Sebert, Lionel Adès, Uwe Platzbecker, Matteo G. Della Porta, et al.

    Acquired somatic mutations are incorporated in the classification and prognosis of myelodysplastic syndromes/neoplasms (MDSs). However, the predictive role of molecular features in MDS needs to be elucidated, especially in the lower-risk subtypes (LR-MDS), where treatment has become heterogeneous and predictive biomarkers are lacking. In this study, we investigated genetic markers associated with erythropoiesis-stimulating agents (ESAs) response in LR-MDS. A European cohort of 535 patients with LR-MDS was analyzed using targeted next-generation sequencing (t-NGS) to calculate molecular prognostic scores (International Prognostic Scoring System, molecular [IPSS-M]). The integration of IPSS-M score among the 2 known variables, serum erythropoietin (sEPO) and transfusion dependence (TD), refined the capability to predict response (area under the curve [AUC], 0.71 vs 0.63, P = .0004). Based on these 3 variables, a molecular predictive score, which we named ESA-PSS-M (–0.05 × [sEPO U/L] –4.5 × [IPSS-M score] –5 × [TD (yes = 1; no = 0)]; specificity 76%; sensitivity 57%), was generated and validated in an external cohort (n = 223 patients with LR-MDS). Despite the impact of IPSS-M score, no single mutated gene was linked to ESA response; however, when we stratified cases by sex at birth, the X-linked STAG2 gene mutations were significantly associated with ESA resistance in males with LR-MDS (odds ratio, 0.13; P = .003). To our knowledge, this is the first study based on a large multicenter cohort of patients suggesting that the integration of IPSS-M score and sex-specific mutations can characterize ESA resistance and guide first-line (1L) therapeutic choices for anemic LR-MDS (ie, ESAs vs luspatercept).


  • Open Access

    Prognostic significance of monocytic-like phenotype in patients with AML treated with venetoclax and azacytidine

    by Lin-Pierre Zhao, Typhaine Dumas-Rivero, Lauren Barette, Lorea Aguinaga, Arij Cheffai, Clémentine Chauvel, Reinaldo Dal Bello, Emmanuel Raffoux, Emmanuelle Clappier, Matthieu Duchmann, et al.

    The prognostic impact of monocytic differentiation in patients with acute myeloid leukemia (AML) receiving venetoclax (Ven) and azacitidine (Aza) remains unclear. In a prospective cohort of 86 newly diagnosed patients with AML treated with Ven-Aza, we used multiparametric flow cytometry (MFC) to define monoblasts as AML blasts coexpressing ≥2 monocytic markers (CD4, CD36, and CD64) per European LeukemiaNet (ELN) guidelines. Patients with higher monoblasts/CD45+ proportions had lower complete response rates (odds ratio, 0.24; P = .005) and significantly shorter overall survival (OS; 4.0 vs 14.9 months; P = .003). A ≥10% monoblasts/CD45+ threshold, identified via maximally selected rank statistics, stratified patients into monoblasthigh (≥10%) and monoblastlow (<10%) groups. MFC reclassified 20% of French-American-British (FAB) non-M4/5 and 15% of FAB M4/5 cases into monoblasthigh and monoblastlow groups, respectively. Multivariable analysis confirmed monoblasthigh status as an independent adverse prognostic factor for OS (hazard ratio [HR], 1.95; P = .023), with a particularly strong impact in ELN 2024 favorable-risk patients (HR, 2.81; P = .024). Our findings highlight monocytic differentiation, assessed via MFC, as a key predictor of Ven-Aza resistance and poor survival, independent of genetic classification. Given its availability in routine diagnostics, MFC-based monocytic assessment could improve AML risk stratification and treatment decisions in patients eligible for less intensive therapies. This trial was registered at www.clinicaltrials.gov as #NCT05326919.


  • Open Access

    Cutaneous clonal mature plasmacytoid dendritic cell dermatosis in patients with myeloid neoplasms

    by Thibault Mahévas, Amélie Osio, Lise Larcher, Emmanuelle Clappier, Werner Kempf, Lionel Adès, Pierre Fenaux, Marie Sébert, Jérémie Delaleu, Marie Jachiet, et al.